Revolution Medicines

Revolution Medicines is a clinical-stage precision oncology company headquartered in Redwood City, California, developing targeted therapies for RAS-addicted cancers. Its pipeline centers on RAS(ON) inhibitors — including daraxonrasib (RMC-6236), zoldonrasib (RMC-9805), and elironrasib (RMC-6291) — designed to directly target the active, GTP-bound (ON) state of oncogenic RAS proteins across mutations such as KRAS G12X. The company pairs structure-based drug discovery with clinical development to pursue treatments for pancreatic, lung, colorectal, and other RAS-driven tumors. Revolution Medicines is a publicly traded corporate entity (Nasdaq: RVMD) and does not currently expose a public developer API surface; this profile captures its identity and domain-security posture for the API Evangelist network.

Revolution Medicines is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Oncology, Biotechnology, and Pharmaceuticals.

🌐 Visit website 📡 Source on GitHub
10.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyLife SciencesOncologyBiotechnologyPharmaceuticalsCancerDrug DiscoveryRAS

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 10.8/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.0 / 20
Commercial Clarity 2.1 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/revolution-medicines: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Revolution Medicines Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy

Company 1

The organization behind the API

Website
Website

Source (apis.yml)

apis.yml Raw ↑ 
aid: revolution-medicines
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/revolution-medicines.png
name: Revolution Medicines
description: 'Revolution Medicines is a clinical-stage precision oncology company headquartered in Redwood City, California,
  developing targeted therapies for RAS-addicted cancers. Its pipeline centers on RAS(ON) inhibitors — including daraxonrasib
  (RMC-6236), zoldonrasib (RMC-9805), and elironrasib (RMC-6291) — designed to directly target the active, GTP-bound (ON)
  state of oncogenic RAS proteins across mutations such as KRAS G12X. The company pairs structure-based drug discovery with
  clinical development to pursue treatments for pancreatic, lung, colorectal, and other RAS-driven tumors. Revolution Medicines
  is a publicly traded corporate entity (Nasdaq: RVMD) and does not currently expose a public developer API surface; this
  profile captures its identity and domain-security posture for the API Evangelist network.'
url: https://raw.githubusercontent.com/api-evangelist/revolution-medicines/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Life Sciences
- Oncology
- Biotechnology
- Pharmaceuticals
- Cancer
- Drug Discovery
- RAS
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.revmed.com
- type: PrivacyPolicy
  url: https://www.revmed.com/privacy-policy/
- type: DomainSecurity
  url: security/revolution-medicines-domain-security.yml
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 1
  pass: local-v1